Program
Monday, May 2rd, 2022
08:30 // Registration and breakfast
09:15 // Welcome
09:30 // SESSION 1: Will molecular tests enable sustainable precision medicine?
Chair: Kristin Austlid Taskén, Oslo University Hospital (NO)
09:30 // How to use new biomarkers in treatment guidance of men with early prostate cancer?
Stacy Loeb, New York University and the Manhattan Veterans Affairs Medical Center (US)
10:00 // Will biomarkers - other than PSA - be used to guide treatment of advanced prostate cancer?
Nicolas Mottet, University Hospital St. Etienne and University Jean Monnet (FR)
10:30 // How cost-effective are biomarkers?
Derya Tilki, Martini-Klinik Prostate Cancer Centre, Hamburg (DE)
11:00 // Break
11:30 // SESSION 2: Providing evidence for implementing molecular tests in clinical guidelines
Chair: Rolf Skotheim, Oslo University Hospital (NO)
11:30 // Requirements for implementation of molecular tests into guidelines
Himisha Beltran, Dana-Farber Cancer Institute and Harvard Medical School (US)
12:00 // Molecular stratification in clinical trials
Johann de Bono, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust (UK)
12:30 // Design of biomarker-driven clinical trials (Sponsored by Tannlege Olaf Aase og Frues legat)
Jason Connor, University of Central Florida's College of Medicine and ConfluenceStat LLC (US)
13:00 // Lunch
14:00 // How to bring molecular tests into the clinic in Scandinavia
Henrik Grönberg, Karolinska Institutet and Capio S:t Göran Hospital (SE)
14:30 // Biomarker-driven precision medicine in Norway - where we are and where to go
Hege Russnes, Oslo University Hospital (NO)
14:45 // Short talk - selected from abstracts
14:55 // Short talk - selected from abstracts
15:05 // Break
15:30 // Panel Discussion (in Norwegian)
- How and when can molecular tests provide sustainable precision medicine in the clinic?
Moderator Elisabeth Kirkeng Andersen (NO)
16:30 // Poster session
18:00 // Social activities and Dinner (including Poster Awards)
Tuesday, May 3rd, 2022
09:00 // SESSION 3: Precision medicine: impact of the tumour environment
Chair: Heidi Lyng, Oslo University Hospital (NO)
09:00 // Everything in balance? Metabolism reprograms cells
Ian Mills, University of Oxford, Queen’s University of Belfast and University of Cambridge (UK)
09:30 // Hypoxia and subclonal evolution
Rob Bristow, Manchester Cancer Research Centre, CRUK Major research Centre, University of Manchester (UK)
10:00 // How can we move forward with immunotherapy in prostate cancer?
Johanna Olweus, Oslo University Hospital (NO)
10:15 // Break
10:45 // Discovery and testing of biomarkers and drugs in ex vivo and in vivo model systems
Wytske van Weerden, Erasmus Medical Center (NL)
11:15 // Biomarker potential of tumor hypoxia
Heidi Lyng, Oslo University Hospital (NO)
11:30 // Lunch
12:30 // Drug efficacy in ex vivo model systems
Olli Kallioniemi, Karolinska Institutet (SE)
13:00 // SESSION 4: Pitfalls and opportunities in biomarker discovery
Alicia Llorente, Oslo University Hospital (NO)
13:00 // Tumor heterogeneity: a challenge to biomarker research
Håvard Danielsen, Oslo University Hospital (NO)
13:15 // Lineage plasticity in prostate cancer
Mark Rubin, University of Bern (CH)
13:45 // Extracellular vesicles - from lab to clinical implementation
Johan Skog, Exosome Diagnostics (US)
14:15 // Break
14:35 // Exploring precision oncology: From gene fusions to lncRNAs
Arul Chinnaiyan, Michigan Center for Translational Pathology and Howard Hughes Medical Institute (US)
15:05 // Multifocal prostate cancer and implications for precision oncology
Rolf Skotheim, Oslo University Hospital (NO)
15:15 // Short talk- selected from abstracts
15:25 // European network for biomarker validation
Guido Jenster, Erasmus Medical Centre (NL)
15:55 // Closing remarks
Sponsors
